Unlocking the full potential of citric acid-synthesized carbon dots as a supercapacitor electrode material via surface functionalization.

This research paper investigates the effect of functionalizing the surfaces of citric acid-synthesized carbon dots (CDs) with hyperbranched bis(methylol)propionic acid (bis-MPA) polyester hydroxyl polymers (HBPs) on their performance as electrode materials in a supercapacitor. Two types of HBPs with 16 and 64 peripheral hydroxyl groups were used to functionalize the CDs' oxygen-enriched surface. Here, CDs were used as electrode materials for the first time in symmetric supercapacitors without a composite material, and how surface modification affects the capacitance performance of CDs was investigated. Our results showed that the functionalization of green-emitting CDs with HBP resulted in the successful passivation of surface defects, which improved their stability and prevented further oxidation. The CDs with HBP passivation exhibited excellent electrochemical performance, with a high specific capacitance of 32.08 F g-1 at 0.1 A g-1 and good rate capability, indicating a faster ion transport rate at high current densities. Experimental EPR spectra of functionalized and non-functionalized CDs reveal distinct changes in g-factor values and line widths, confirming the impact of dangling bonds and spin-orbit interactions. The observed broader linewidth indicates a wider range of electron spin resonances due to energy-level splitting induced by spin-orbit coupling. The excellent electrochemical performance of CDs with HBP passivation can be attributed to the presence of oxygen-containing surface functional groups such as hydroxyl and carboxyl groups on their surfaces, which enhance the conductivity and charge transfer reactions. These results suggest that functionalization with polar HBPs is a promising strategy to enhance the electrochemical performance of CDs in supercapacitor applications.

Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants are expected to be resistant to Bebtelovimab (BEB) monoclonal antibody (MAb) and the real-world experience regarding its effectiveness is scarce. This retrospective cohort study reports a data analysis in Banner Healthcare System (a large not-for-profit organization) between 4/5/2022 and 8/1/2022 and included 19,778 Coronavirus disease-19 (COVID-19) positive (by PCR or direct antigen testing) patients who were selected from Cerner-Electronic Health Record after the exclusions criteria were met. The study index date for cohort was determined as the date of BEB MAb administration or the date of the first positive COVID-19 testing. The cohort consist of COVID-19 infected patients who received BEB MAb (N = 1,091) compared to propensity score (PS) matched control (N = 1,091). The primary composite outcome was the incidence of 30-day all-cause hospitalization and/or mortality. All statistical analyses were conducted on the paired (matched) dataset. For the primary composite outcome, the event counts and percentages were reported. Ninety-five percent Clopper-Pearson confidence intervals for percentages were computed. The study cohorts were 1:1 propensity matched without replacement across 26 covariates using an optimal matching algorithm that minimizes the sum of absolute pairwise distance across the matched sample after fitting and using logistic regression as the distance function. The pairs were matched exactly on patient vaccination status, BMI group, age group and diabetes status. Compared to the PS matched control group (2.6%; 95% confidence interval [CI]: 1.7%, 3.7%), BEB MAb use (2.2%; 95% CI: 1.4%, 3.3%) did not significantly reduce the incidence of the primary outcome (p = 0.67). In the subgroup analysis, we observed similar no-difference trends regarding the primary outcomes for the propensity rematched BEB MAb treated and untreated groups, stratified by patient vaccination status, age (<65 years or ≥65), and immunocompromised status (patients with HIV/AIDS or solid organ transplants or malignancy including lymphoproliferative disorder). The number needed to treat (1/0.026-0.022) with BEB MAb was 250 to avoid one hospitalization and/or death over 30 days. The BEB MAb use lacked efficacy in patients with SARS-CoV-2 Omicron subvariants (mainly BA.2, BA.2.12.1, and BA.5) in the Banner Healthcare System in the Southwestern United States.

The Impact of Nirmatrelvir-Ritonavir in Reducing Hospitalizations Among High-Risk Patients With SARS-CoV-2 During the Omicron Predominant Era.

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has caused significant morbidity and mortality in high-risk populations. Several therapeutics have been developed to reduce the risk of complications related to COVID-19, hospitalizations, and death. In several studies, nirmatrelvir-ritonavir (NR) was reported to reduce the risk of hospitalizations and death. We aimed to evaluate the efficacy of NR in preventing hospitalizations and death during the Omicron predominant period. METHODS: We retrospectively evaluated patients from June 1, 2022, through September 24, 2022. There were a total of 25,939 documented COVID-19 cases. Using propensity matching, we matched 5754 patients treated with NR with untreated patients. RESULTS: Postmatching, the median age of the NR-treated group was 58 years (interquartile range, 43-70 years) and 42% were vaccinated. Postmatching composite outcome of the 30-day hospitalization and mortality in the NR-treated group were 0.9% (95% confidence interval [CI]: 0.7%-1.2%) versus 2.1% (95% CI: 1.8%-2.5%) in the matched control group, with a difference of -1.2 (-1.7, -0.8), P value <.01. The difference rates (NR vs. control) in 30-day all-cause hospitalizations and mortality were -1.2% (95% CI: -1.6% to -0.7%, P value <.01) and -0.1% (95% CI: -0.2% to 0.0%, P value = 0.29), respectively. We found similar finding across different age groups (≥65 vs. <65) and the vaccinated group. CONCLUSION: We report a significant benefit with the use of NR in reducing hospitalizations among various high-risk COVID-19 groups during the Omicron BA.5 predominant period.

Utilization of hepatitis C virus-positive donors in kidney transplantation.

PURPOSE OF REVIEW: Direct-acting antivirals (DAA) have transformed kidney transplantation by increasing the donor pool from hepatitis C virus (HCV)-infected donors and allowing HCV nucleic acid amplification testing (NAT) donor-positive/recipient-negative (D+/R-) transplantation over the last 7 years. Willingness to accept kidneys from HCV-infected donors and timing/duration of DAA therapy have been evolving. RECENT FINDINGS: By 2021, most of the HCV NAT+ kidneys (92.6%) were transplanted to HCV-naive recipients. Despite the availability of effective DAA therapy, the discard rate of HCV NAT kidneys has been stagnant around 25%. The proportion of wait-listed patients willing to accept a deceased donor kidney from HCV Ab+ and HCV NAT+ donors increased 20-fold between 2015 and 2022. Wait-listed time to receive HCV NAT+ kidneys has been rising and most of the kidneys are transplanted to HCV-naive recipients. The proportion of deceased donor kidney transplants performed in recipients with HCV seropositivity decreased from 5.1 to 2.8% during the same period. Relatively short courses of DAA therapy (7-8 days) appear to be effective to decrease HCV transmission (<5%) and achieve sustained virological response at 12 weeks if administered prior to revascularization. SUMMARY: Further studies are needed to evaluate long-term outcomes of HCV NAT D+/R- transplantation and the best course of DAA treatment.

The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab-Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center.

BACKGROUND: Coronavirus disease 2019 (COVID-19) is associated with increased morbidity and mortality among immunocompromised patients. Tixagevimab-cilgavimab (Tix-Cil) is a combination of 2 monoclonal antibodies approved for the prevention of COVID-19 complications in this high-risk group. METHODS: We retrospectively reviewed the charts of patients who received Tix-Cil during the Omicron variant period (January 17 to April 23, 2022), with a follow-up period until May 24, 2022. We collected data about patient underlying comorbidities and post Tix-Cil COVID-19 infections, deaths, and hospitalizations. RESULTS: There were 463 patients with a median age of 68 years, of which 51% were male, 79% White, 13.2% Hispanic, 1.7% Black/African American, and 5.8% identified as Other. A total of 18% had undergone a solid organ transplantation or hematopoietic stem cell transplantation. Only 6/98 (6.1%) had severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detected by polymerase chain reaction (PCR) at a median 48 days (interquartile range [IQR] 27.5, 69) follow-up. Forty-two patients (9.1%) were hospitalized, and 4 (0.9%) died, but none were attributed to COVID-19 or Tix-Cil. One hospitalized patient had an incidental, asymptomatic, positive SARS-CoV 2 by PCR. The median days from Tix-Cil administration to non-COVID-19-related hospitalization and death were 30 (IQR 17, 55) and 53 (IQR 18, 91), respectively. CONCLUSION: Tix-Cil provides protection against COVID-19 complications in immunocompromised patients with suboptimal immune responses to vaccines.

Erratum: Evaluation of Suspected COVID-19 Patients in a Pediatric Emergency Department.

[This corrects the article DOI: 10.1055/s-0041-1735493.].

A novel scoring system (YASHMA) predicting brain injury in asphyxiated newborns.

BACKGROUND: Hypoxic-ischemic encephalopathy is a complication of adverse intrapartum events and birth asphyxia resulting in brain injury and mortality in late preterm and term newborns. OBJECTIVES: In this study, we aimed to predict brain damage on magnetic resonance imaging (MRI) with a new scoring system. METHODS: Yieldly And Scorable Holistic Measuring of Asphyxia (YASHMA) is generated for detection of brain injury in asphyxiated newborns. Total scores were calculated according to scores of birth weight, gestation weeks, APGAR scores at first and fifth minutes, aEEG patterns and epileptic status of patients. The major outcome of the scoring system was to determine correlation between poor scores and neonatal brain injury detected on MRI. RESULTS: In hypothermia group with brain injury, low gestational weeks and lowest APGAR scores, abnormal aEEG findings were statistically different from others. YASHMA scores were statistically significant with high sensitivity, specificity, AUC and 95% confidence interval values. CONCLUSIONS: YASHMA scoring system is feasible and can be suggestive for detecting brain injury in low-income countries.

Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection.

Background: Real-world data on the effectiveness of neutralizing casirivimab-imdevimab monoclonal antibody (Cas-Imd mAb) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among high-risk patients may inform the response to future SARS-CoV-2 variants. Methods: This study covers an observational retrospective data analysis in Banner Health Care System sites, mainly in Arizona. During the study period, the prevalence of SARS-CoV-2 Delta variant was between 95% and 100%. Of 29 635 patients who tested positive for coronavirus disease 2019 (COVID-19) between 1 August 2021 and 30 October 2021, in the Banner Health Care System, the study cohort was split into 4213 adult patients who received Cas-Imd mAb (1200 mg) treatment compared to a PS-matched 4213 untreated patients. The primary outcomes were the incidence of all-cause hospitalization, intensive care unit (ICU) admission, and mortality within 30 days of Cas-Imd mAb administration or Delta variant infection. Results: Compared to the PS-matched untreated cohort, the Cas-Imd mAb cohort had significantly lower all-cause hospitalization (4.2% vs 17.6%; difference in percentages, -13.4 [95% confidence interval {CI}, -14.7 to -12.0]; P < .001), ICU admission (0.3% vs 2.8%; difference, -2.4 [95% CI, -3.0 to -1.9]; P < .001), and mortality (0.2% vs 2.0%; difference, -1.8 [95% CI, -2.3 to -1.3]; P < .001) within 30 days. The Cas-Imd mAb treatment was associated with lower rate of hospitalization (hazard ratio [HR], 0.22 [95% CI, .19-.26]; P < .001) and mortality (HR, 0.11 [95% CI, .06-.21]; P < .001). Conclusions: Cas-Imd mAb treatment was associated with a lower hospitalization rate, ICU admission, and mortality within 30 days among patients infected with the SARS-CoV-2 Delta variant.

Evaluation of Suspected COVID-19 Patients in a Pediatric Emergency Department.

Coronavirus disease 2019 (COVID-19) is now a global pandemic. The aim of this study was to investigate the prevalence of COVID-19 in pediatric patients and to compare the characteristics of positive and negative patients. This study conducted from March to May 2020 in a tertiary children's hospital. Patients were included if they were under 18 years old and a SARS-CoV-2 polymerase chain reaction test had been performed. Of the 1,812 patients included in the study, 365 (20.1%) were positive for COVID-19. The median age was 102 months in the positive group, 70 months in the negative group ( p < 0.001). The sex distribution was almost equal. Nearly all positive patients had been in close contact with a COVID-19 infected family household member ( p < 0.001). The most common symptoms were fever (54.4%) and cough (38.6%). The asymptomatic patient rate was higher in the positive group ( p < 0.001). Lymphopenia (<1500/mm 3 ) was found in 29.9% of the positive children ( p = 0.005). When the groups were compared, white blood cell, neutrophil, lymphocyte, and platelet counts; neutrophil-to-lymphocyte ratio; and C-reactive protein level were lower in the positive group. Chest radiography was performed in 95.3% of the positive patients, and the results of 29.7% of them were interpreted as pathological ( p < 0.001). Most of the pediatric patients had a history of contact with COVID-19 positive individuals, and therefore, the diagnosis is generally suspected from a history of household exposure to COVID-19. Lymphopenia can help predict positivity. Awareness, reinforcing infection control measures, and performing health management within families are important steps to manage these patients.

Outcomes of Simultaneous Liver-Kidney Transplantation Using Kidneys of Deceased Donors With Acute Kidney Injury.

Outcomes from simultaneous liver-kidney transplantation (SLKT) when using kidneys from donors with acute kidney injury (AKI) have not been studied. We studied 5344 SLKTs between May 1, 2007, and December 31, 2019, by using Organ Procurement and Transplantation Network registry data supplemented with United Network for Organ Sharing-DonorNet data. Designating a donor as having AKI required by definition that the following criteria were met: (1) the donor's condition aligned with the Kidney Disease: Improving Global Outcomes (KDIGO) international consensus guidelines and the terminal serum creatinine (Scr) level was ≥1.5 times the minimum Scr level for deceased donors before organ recovery and (2) the terminal Scr level was ≥1.5 mg/dL (a clinically meaningful and intuitive Scr threshold for defining AKI for transplant providers). The primary outcomes were liver transplant all-cause graft failure (ACGF; defined as graft failures and deaths) and kidney transplant death-censored graft failure (DCGF) at 1 year after transplant. The donors with AKI were young, had good organ quality, and had a short cold ischemia time. In the study cohort, 4482 donors had no AKI, whereas 862 had AKI (KDIGO AKI stages: 1, n = 521; 2, n = 202; and 3, n = 138). In the group with AKI and the group with no AKI, respectively, liver ACGF at 1 year (11.1% versus 12.9% [P = 0.13]; hazard ratio [HR], 1.20; 95% confidence interval [CI], 0.97-1.49) and kidney DCGF at 1 year (4.6% versus 5.7% [P = 0.18]; HR, 1.27; 95% CI, 0.95-1.70) did not differ in the full multivariable Cox proportional hazard models. Selected kidneys from deceased donors with AKI can be considered for SLKT.

Implications of changing synchronization in propulsive performance of side-by-side pitching foils.

The unsteady hydrodynamics of side-by-side pitching foils are studied numerically at Reynolds number of 4000 with altering phase differences in the middle of an oscillation cycle. This represents a change in synchronization of oscillating foils, inspired by experimental observations on group swimming of red nose tetra fish. The hybrid oscillation cases are based on an initially out-of-phase pitching that switch to in-phase at the 20th cycle of oscillation. Various sequential combinations of out-of-phase and in-phase pitching are also examined in terms of foil propulsive performance. It is observed that out-of-phase pitching foils initially produce zero total side-force. However, they start producing negative total side-force after 13 oscillation cycles. Contrarily for the in-phase oscillation cases, the initially positive total side-force reverted to zero over time. In hybrid oscillation cases, the negative total side-force produced during the initial out-of-phase oscillations abruptly adjusted to zero following a change of synchronization that led to in-phase oscillations, which is inspired from a particular swimming behavior in fish. Based on three hybrid modes, defined on the onset of mid-cycle switch to in-phase oscillations, it was apparent that the benefit of synchronization, or there lack of, greatly depended on the timing of the change in synchronization. Thus, mid-swimming change of synchronization in side-by-side systems inspired by fish schools compensates for their non-zero total side-force production to maintain their lateral position. Such changes do not translate to significant gains in neither thrust generation nor efficiency.

Effectiveness of vibrational forces on orthodontic treatment : A randomized, controlled clinical trial.

AIM: AcceleDent® Aura (OrthoAccel® Technologies, Bellaire, TX, USA) is a class II medical device with U.S. Food and Drug Administration approval that uses SoftPulse Technology™ to increase the speed of tooth movement. The aim of this study was to evaluate the application of vibrational forces on the rate of canine distalization. METHODS: A total of 20 patients (10 boys and 10 girls) who had class II division 1 malocclusion or severe crowding and indicated first premolar extractions for treatment were included in the study. The patients were divided into two groups: 8 in the control group and 12 in the study group. Three-dimensional digital models were taken just before canine distalization and after space closure using the 3Shape TRIOS® R700 (3Shape Inc., Copenhagen, Denmark) device. Linear measurements between molars and canines were evaluated. The results were assessed with SPSS 23.0 program (IBM, Armonk, NY, USA). RESULTS: One subject was excluded from the study group due to insufficient oral hygiene and poor patient compliance. Tooth movement rates were 1.06 mm/month for mandibular and maxillary canine teeth in the control group. In the study group, tooth movement rates were 1.24 mm/month for maxillary canines and 1.09 mm/month for mandibular canines. These differences were not statistically significant (p > 0.05). CONCLUSION: AcceleDent® Aura is an easy-to-use device; however, in our study its application did not have any positive effects on canine retraction rates.

An Atypical Paediatric Optic Nerve Sheath Meningioma.

A 16-year-old male presented with a three year history of right proptosis. All other ocular findings were normal. Imaging demonstrated a large, calcified, contrast-enhancing mass in the apical orbit. The tumour had high gallium-68-DOTATATE uptake and low 18F-2-fluoro-2-deoxy-D-glucose uptake. An incisional biopsy revealed a diagnosis of psammomatous optic nerve sheath meningioma (ONSM). One year later stereotactic radiotherapy was performed due to tumour growth. Tumour size and visual acuity remained stable in the six months after treatment. This case differs from previously reported paediatric ONSMs by its histo-clinical characteristics (exophytic-calcified mass, visual preservation, psammomatous histology).

A case of infective endocarditis due to Herbaspirillum Huttiense in a pediatric oncology patient.

Infective endocarditis (IE) is an infection of the endocardium and/or heart valves that involves thrombus formation (vegetation). This condition might damage the endocardial tissue and/or valves. An indwelling central venous catheter is a major risk factor for bacteremia at-risked pediatric populations such as premature infants; children with cancer and/or connective tissue disorders. Herbaspirillum huttiense is a Gram-negative opportunistic bacillus that may cause bacteremia and pneumonia rarely in this fragile population. Herein we report the very first case of bacteremia and IE in a pediatric oncology patient caused by H. huttiense.

Wake symmetry impacts the performance of tandem hydrofoils during in-phase and out-of-phase oscillations differently.

The hydrodynamics of two oscillating foils in side-by-side configuration is numerically investigated for in-phase and out-of-phase pitching at Reynolds number of 4000 and Strouhal numbers of St=0.25-0.5. The effects of phase difference (in-phase and out-of-phase) and Strouhal number on symmetric attributes of the wake and unsteady propulsive performance of the foils are studied in detail. At lower Strouhal numbers, there is a quasisteady performance in both thrust generation and power consumption, which coincides with persistence of the wake symmetry. As Strouhal number increases, however, in-phase and out-of-phase pitching display unsteady cycle-averaged behavior with very different wake characteristics. The asymmetric wake of in-phase pitching foils at high Strouhal numbers transitions to a quasisymmetric wake, when an extensive interaction between the two vortex streets is observed in the wake. This coincides with an improvement on the propulsive performance of the foils. In contrast, the symmetric wake of the out-of-phase pitching foils at a high Strouhal number transitions to an asymmetric wake. The adverse effect of this transition is only observed on the propulsive performance of one foil while the other exploits the wake towards a better performance. The collective performance of the the out-of-phase pitching system, however, remains unchanged. There is also a strong correlation between the wake symmetric characteristics and total nonzero side-force production.

Feeling the power: robust supercapacitors from nanostructured conductive polymers fostered with Mn2+ and carbon dots.

Polyaniline (PANI) is considered one of the most preferred electrically conductive polymers (CPs), which is widely studied as an electrode material in designing next-generation energy storage devices due to their chemical stability, fast redox reactions between the polymer and the electrolytes, high electrical conductivity, excellent electrochemical performance, and low cost. However, the inferior stability of PANI limits its application. In this work, the benefit of carbon dots (CDots) as light-weight and spherical carbon-based electrodes and fillers that allow the maintenance of the nanostructure of PANI while easing the ionic transport was studied together with the effect of manganese(ii) (Mn2+) doping on the overall capacitive properties of PANI. The integration of N-doped spherical, nanosized carbon dots (N-CDots) in the copolymerization of nanostructured PANI in the presence of varying concentrations of Mn2+ as a dopant synergistically improved the overall conductivity and specific surface area of the PANI-based electrode and showed surface double layer ion exchange. Pseudocapacitance mechanisms were observed when the dopant concentration was kept at a molar percentage of Mn2+ to aniline of 1, which displayed exceptionally high specific capacitances of up to 595 F g-1. The asymmetric supercapacitor devices made with N-CDot and nanostructured hybrid electrodes could reveal the great potential in the development of cheap yet efficient battery-sized supercapacitor devices. In addition to extensive electrochemical performance, advanced EPR spectroscopy revealed detailed information regarding the defect structures of electrode materials in terms of understanding the conduction behavior of defect centers.

Effects of skeletally anchored Class II elastics: A pilot study and new approach for treating Class II malocclusion.

OBJECTIVE: To evaluate the skeletal, dentoalveolar, and soft tissue effects of skeletally anchored Class II elastics and compare them with a matched control group treated by a monobloc appliance for the correction of skeletal Class II malocclusion due to mandibular retrusion. MATERIALS AND METHODS: Twelve patients (6 girls, 6 boys) were randomly divided into two groups. In the elastics group, six patients (12.9 ± 1.5 years of age; 3 boys, 3 girls) were treated with skeletally anchored Class II elastics. Two miniplates were placed bilaterally at the ramus of the mandible and the other two miniplates were placed at the aperture piriformis area of the maxilla. In the monobloc group (3 boys and 3 girls; mean age, 12.3 ± 1.6 years), patients used the monobloc appliance. The changes observed in each phase of treatment were evaluated using the Wilcoxon matched-pair sign test. Intergroup comparisons at the initial phase of treatment were analyzed by the Mann-Whitney U test. RESULTS: There were statistically significant group differences in Co-Gn, B-VRL, U1-PP, U1-VRL, Ls-VRL, with significant increases in these parameters in the elastics group (P < .05). The mandibular incisors were protruded in the monobloc group (5.45 ± 1.23°), whereas they were retruded in the elastics group (-3.01 ± 1.66°; P < .01). CONCLUSIONS: The undesirable dentoalveolar effects of the monobloc appliance were eliminated by using miniplate anchorage. Favorable skeletal outcomes can be achieved by skeletal anchorage therapies which could be an alternative to treat skeletal Class II patients with mandibular deficiency.